trending Market Intelligence /marketintelligence/en/news-insights/trending/xslahdlkncq5fclsumxwxw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Guardant Health, AstraZeneca team up on lung cancer blood test for Tagrisso

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Guardant Health, AstraZeneca team up on lung cancer blood test for Tagrisso

Guardant Health Inc. has partnered with AstraZeneca PLC to develop a diagnostic test to go along with the Cambridge, U.K.-based company's non-small cell lung cancer drug Tagrisso.

The blood test, called a companion diagnostic because it corresponds to a specific treatment, is based on Guardant's platform Guardant360, and helps identify non-small cell lung cancer, or NSCLC, patients who might respond well to Tagrisso.

Guardant and AstraZeneca did not reveal the financial terms of the partnership.

Also part of the deal, Guardant plans to use its GuardantOmni platform as a companion diagnostic to AstraZeneca's Imfinzi, also for NSCLC.

The door is also open for more diagnostics from Guardant to be used for AstraZeneca's other programs, Guardant said in a Dec. 13 press release.

"Precision medicine is at the heart of our ambition to eliminate cancer as a cause of death," said Ruth March, senior vice president of precision medicine and genomics at AstraZeneca. "We are committed to matching life-changing medicines to patients most likely to benefit, and we believe our partnership with Guardant Health will help us achieve this."